001     298614
005     20250216015205.0
024 7 _ |a 10.1016/j.jgo.2025.102195
|2 doi
024 7 _ |a pmid:39919652
|2 pmid
024 7 _ |a 1879-4068
|2 ISSN
024 7 _ |a 1879-4076
|2 ISSN
024 7 _ |a altmetric:174093234
|2 altmetric
037 _ _ |a DKFZ-2025-00314
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Li, Keva
|b 0
245 _ _ |a Age-stratified analysis of health-related quality of life in patients with early-stage breast cancer receiving adjuvant radiation therapy and endocrine therapy.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1739198492_28365
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Health-related quality of life (HRQoL) in older patients with breast cancer (BC) (≥70 years) is not well studied. This study assesses aging-related differences in patient-reported outcomes among estrogen receptor-positive (ER+) patients with BC treated with breast conservation surgery (BCS), radiation therapy (RT), and endocrine therapy (ET).Among the 2,057 patients with ER+ early-stage BC enrolled in the prospective multicenter REQUITE study, 1,003 patients receiving adjuvant RT + ET as the only systemic therapy constitute our study population. Patients were stratified by age into younger (<70 years, n = 810 patients) and older (≥70 years, n = 193 patients) groups. Prospectively collected HRQoL was measured using the validated European Organization for Research and Treatment of Cancer (EORTC) quality of life of cancer patients (QLQ-30) and breast cancer-specific quality of life (QLQ-BR23), and Multidimensional Fatigue Inventory (MFI-20) measures at baseline following BCS and pre-adjuvant treatment, post-RT, and at one-year, two-year, and three-year intervals. Statistical analysis involved a mixed model analysis of variance, weighted by propensity scoring.Older patients had a higher burden of comorbidities, larger tumor size, and higher rates of N1 disease compared to the younger group. RT boost to the lumpectomy site was more often delivered in younger participants (72 %) compared to older (50 %). Younger patients predominately received tamoxifen (63.5 %), while older patients more commonly received aromatase inhibitors (67.4 %). Throughout the follow-up, we observed that the younger patients showed greater recovery in QoL domains including sexual enjoyment, systemic side effects, breast symptoms, global health status, and emotional, physical, and social functioning compared to the older group. Cognitive function, which declined from baseline in both groups, improved over time in younger participants but persisted at lower levels in older patients at the three-year follow-up period.Adjuvant treatments differentially impacted HRQoL, with older patients experiencing greater and more persistent adverse effects compared to younger counterparts. These findings underscore the need for tailored interventions that address the unique challenges in HRQoL recovery among older BC survivors.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Early-stage breast cancer, estrogen receptor positive
|2 Other
650 _ 7 |a Endocrine therapy
|2 Other
650 _ 7 |a Health-related quality of life
|2 Other
650 _ 7 |a Lumpectomy
|2 Other
650 _ 7 |a Older women
|2 Other
650 _ 7 |a Patient-reported outcomes
|2 Other
650 _ 7 |a Radiation therapy
|2 Other
700 1 _ |a Chadha, Manjeet
|b 1
700 1 _ |a Moshier, Erin
|b 2
700 1 _ |a Rosenstein, Barry S
|b 3
700 1 _ |a consortium, REQUITE
|b 4
|e Collaboration Author
700 1 _ |a Jandu, Harkeran K
|b 5
|e Contributor
700 1 _ |a Veal, Colin D
|b 6
|e Contributor
700 1 _ |a Fachal, Laura
|b 7
|e Contributor
700 1 _ |a Luccarini, Craig
|b 8
|e Contributor
700 1 _ |a Aguado-Barrera, Miguel E
|b 9
|e Contributor
700 1 _ |a Altabas, Manuel
|b 10
|e Contributor
700 1 _ |a Azria, David
|b 11
|e Contributor
700 1 _ |a Baten, Adinda
|b 12
|e Contributor
700 1 _ |a Bourgier, Celine
|b 13
|e Contributor
700 1 _ |a Bultijnck, Renée
|b 14
|e Contributor
700 1 _ |a Colciago, Riccardo R
|b 15
|e Contributor
700 1 _ |a Farcy-Jacquet, Marie-Pierre
|b 16
|e Contributor
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 17
|e Contributor
700 1 _ |a Choudhury, Ananya
|b 18
|e Contributor
700 1 _ |a Dunning, Alison
|b 19
|e Contributor
700 1 _ |a Elliott, Rebecca M
|b 20
|e Contributor
700 1 _ |a Green, Sheryl
|b 21
|e Contributor
700 1 _ |a Gutiérrez-Enríquez, Sara
|b 22
|e Contributor
700 1 _ |a Herskind, Carsten
|b 23
|e Contributor
700 1 _ |a Lambrecht, Maarten
|b 24
|e Contributor
700 1 _ |a Monten, Christel
|b 25
|e Contributor
700 1 _ |a Rancati, Tiziana
|b 26
|e Contributor
700 1 _ |a Reyes, Victoria
|b 27
|e Contributor
700 1 _ |a De Ruysscher, Dirk
|b 28
|e Contributor
700 1 _ |a De Santis, Maria Carmen
|b 29
|e Contributor
700 1 _ |a Seibold, Petra
|0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
|b 30
|e Contributor
700 1 _ |a Sperk, Elena
|b 31
|e Contributor
700 1 _ |a Veldwijk, Marlon R
|b 32
|e Contributor
700 1 _ |a Symonds, R Paul
|b 33
|e Contributor
700 1 _ |a Stobart, Hilary
|b 34
|e Contributor
700 1 _ |a Taboada-Valladares, Begoña
|b 35
|e Contributor
700 1 _ |a Vega, Ana
|b 36
|e Contributor
700 1 _ |a Veldeman, Liv
|b 37
|e Contributor
700 1 _ |a Webb, Adam J
|b 38
|e Contributor
700 1 _ |a Weltens, Caroline
|b 39
|e Contributor
700 1 _ |a West, Catharine M
|b 40
|e Contributor
700 1 _ |a Rattay, Tim
|b 41
|e Contributor
700 1 _ |a Talbot, Christopher J
|b 42
|e Contributor
773 _ _ |a 10.1016/j.jgo.2025.102195
|g Vol. 16, no. 2, p. 102195 -
|0 PERI:(DE-600)2556813-9
|n 2
|p 102195
|t Journal of geriatric oncology
|v 16
|y 2025
|x 1879-4068
909 C O |o oai:inrepo02.dkfz.de:298614
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 30
|6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J GERIATR ONCOL : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-16
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21